Cullinan Oncology Llc Stock Analysis

Cullinan Stock Analysis Notes

About 95.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.53. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cullinan Oncology LLC recorded a loss per share of 3.06. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 31st of August 2009. Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Cullinan Management operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. For more info on Cullinan Oncology LLC please contact Nadim Ahmed at 617 410 4650 or go to https://cullinantherapeutics.com.

Cullinan Oncology LLC Investment Alerts

Cullinan Oncology LLC Upcoming and Recent Events

Cullinan Largest EPS Surprises

View All Earnings Estimates

Cullinan Oncology Environmental, Social, and Governance (ESG) Scores

Cullinan Stock Institutional Investors

Note, although Cullinan Oncology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cullinan Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 972.27 M.

Cullinan Profitablity

Management Efficiency

Cullinan Oncology LLC has return on total asset (ROA) of (0.1904) % which means that it has lost $0.1904 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2494) %, meaning that it created substantial loss on money invested by shareholders. Cullinan Oncology's management efficiency ratios could be used to measure how well Cullinan Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of October 2024, Return On Tangible Assets is likely to grow to -0.3. In addition to that, Return On Capital Employed is likely to grow to -0.4. At this time, Cullinan Oncology's Total Assets are very stable compared to the past year. As of the 19th of October 2024, Other Current Assets is likely to grow to about 13.8 M, while Non Current Assets Total are likely to drop about 4.7 M.

Technical Drivers

As of the 19th of October, Cullinan Oncology shows the Risk Adjusted Performance of (0.01), standard deviation of 3.42, and Mean Deviation of 2.57. Cullinan Oncology LLC technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cullinan Oncology LLC standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and kurtosis to decide if Cullinan Oncology LLC is priced correctly, providing market reflects its regular price of 16.77 per share. Given that Cullinan Oncology has information ratio of (0.05), we suggest you to validate Cullinan Oncology LLC's prevailing market performance to make sure the company can sustain itself at a future point.

Cullinan Oncology LLC Price Movement Analysis

Cullinan Oncology LLC Insider Trading Activities

Cullinan Oncology Outstanding Bonds

Cullinan Oncology Predictive Daily Indicators

Cullinan Oncology Corporate Filings

Cullinan Oncology Forecast Models

Cullinan Oncology's time-series forecasting models are one of many Cullinan Oncology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cullinan Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cullinan Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cullinan shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cullinan Oncology. By using and applying Cullinan Stock analysis, traders can create a robust methodology for identifying Cullinan entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cullinan analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cullinan analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cullinan Oncology LLC stock analysis indicators help investors evaluate how Cullinan Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cullinan Oncology shares will generate the highest return on investment. By understating and applying Cullinan Oncology stock analysis, traders can identify Cullinan Oncology position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.